Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

Stopped early · Phase 2

Conditions studied: Ocular Inflammation

In brief

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.

Key facts

Study ID

NCT01214174

Run by

ICON Bioscience Inc

People needed

42

Starts

2010-10-01

Expected to finish

2012-05-01

Last updated by the study team

2013-09-18

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.

You may not qualify if…

• Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.
• Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
• Patients with any signs of intraocular inflammation in either eye at screening.
• Patients who have received any prior intravitreal injections in the study eye.

Where it is running

• Drs. Fine, Hoffman, and Packer — Eugene, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.